<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952482</url>
  </required_header>
  <id_info>
    <org_study_id>201603025RIND</org_study_id>
    <nct_id>NCT02952482</nct_id>
  </id_info>
  <brief_title>Newborn Screening for Adrenoleukodystrophy</brief_title>
  <official_title>Newborn Screening for Adrenoleukodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test if the routine newborn screening dried blood spots can be used to test if elevation
      of C26:0 lysophosphatidylcholine (C26:0-lyso-PC), a status indicating adrenoleukodystrophy
      (ALD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parents of newborns will be invited to test if their newborns are affected with ALD. The
      routine newborn screening dried blood spots sample will be used to test the concentration of
      C26:0-lyso-PC . If positive of a screening test, further confirmation tests including
      physical examination and other methodology for ALD confirmation will be provided. Genetic
      counseling and treatment option will be provided, too.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of newborn with ALD</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">45796</enrollment>
  <condition>Adrenoleukodystrophy</condition>
  <arm_group>
    <arm_group_label>newborns testing for ALD</arm_group_label>
    <description>newborns testing for ALD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>newborns testing for ALD</intervention_name>
    <description>Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC</description>
    <arm_group_label>newborns testing for ALD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        newborns whose parents agree to be tested
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Babies born in Taiwan receive regular newborn screening suggested by Ministry of Heath
             and Welfare.

          -  Parents or Legal Guardian sign in the informed consent form.

        Exclusion Criteria:

          -  Parents or Legal Guardian do not agree to sign in the informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adrenoleukodystrophy</keyword>
  <keyword>C26:0-lyso-PC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

